Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban

被引:43
作者
Fawole, Adewale [1 ]
Daw, Hamed A. [2 ,3 ]
Crowther, Mark A. [4 ,5 ,6 ]
机构
[1] Fairview Hosp, Dept Internal Med, Cleveland, OH USA
[2] Fairview Hosp, Cleveland Clin, Ctr Canc, Cleveland, OH USA
[3] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA
[4] McMaster Univ, Div Hematol & Thromboembolism, Hamilton, ON, Canada
[5] Hamilton Reg Lab Med Program, Lab Med, Hamilton, ON, Canada
[6] McMaster Univ, Hamilton, ON L8S 4L8, Canada
关键词
DIRECT THROMBIN INHIBITOR; FACTOR-XA INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATE; INTERNATIONAL NORMALIZED RATIO; ATRIAL-FIBRILLATION; PLASMA-CONCENTRATIONS; AMERICAN-COLLEGE; REVERSAL AGENTS; IN-VITRO; PHARMACOKINETICS;
D O I
10.3949/ccjm.80a.13025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and are alternatives to warfarin. However, many physicians are wary of these drugs, since there is limited evidence on how to manage bleeding in patients taking them, and since no specific antidote is known to reverse their anticoagulant effect. Management requires careful adherence to first principles of bleeding care. Unapproved and untested reversal strategies may be required in patients with life-threatening bleeding.
引用
收藏
页码:443 / 451
页数:9
相关论文
共 48 条
[1]  
[Anonymous], HAEMATOL HEMATOL S1
[2]   Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay [J].
Barrett, Yu Chen ;
Wang, Zhaoqing ;
Frost, Charles ;
Shenker, Andrew .
THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) :1263-1271
[3]   A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays [J].
Carlsson, SC ;
Mattsson, C ;
Eriksson, UG ;
Sarich, TC ;
Wåhlander, K ;
Eliasson, Å ;
Karlson, BW ;
Sheth, SB ;
Held, P .
THROMBOSIS RESEARCH, 2005, 115 (1-2) :9-18
[4]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[5]   Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents [J].
Crowther, M. A. ;
Warkentin, T. E. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 :107-110
[6]   Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease [J].
Cullberg, M ;
Eriksson, UG ;
Larsson, M ;
Karlsson, MO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (01) :71-79
[7]   Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].
Eerenberg, Elise S. ;
Kamphuisen, Pieter W. ;
Sijpkens, Meertien K. ;
Meijers, Joost C. ;
Buller, Harry R. ;
Levi, Marcel .
CIRCULATION, 2011, 124 (14) :1573-1579
[8]   Safety of factor VIII inhibitor bypass activity (FEIBA®):: 10-year compilation of thrombotic adverse events [J].
Ehrlich, HJ ;
Henzl, MJ ;
Gomperts, ED .
HAEMOPHILIA, 2002, 8 (02) :83-90
[9]   Adverse impact of bleeding on prognosis in patients with acute coronary syndromes [J].
Eikelboom, John W. ;
Mehta, Shamir R. ;
Anand, Sonia S. ;
Xie, Changchun ;
Fox, Keith A. A. ;
Yusuf, Salim .
CIRCULATION, 2006, 114 (08) :774-782
[10]   Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty [J].
Eriksson, Bengt I. ;
Borris, Lars C. ;
Friedman, Richard J. ;
Haas, Sylvia ;
Huisman, Menno V. ;
Kakkar, Ajay K. ;
Bandel, Tiemo J. ;
Beckmann, Horst ;
Muehlhofer, Eva ;
Misselwitz, Frank ;
Geerts, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (26) :2765-2775